Skip to main content

Table 1 Lifestyle and clinical factors of 1,037 newly diagnosed T2 DM patients in the Danish population-based DD2 project according to CRP levels and stratified on gender, with corresponding relative risks (RR) for elevated CRP

From: Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort

 

Females

Males

 

CRP levels <3.0 mg/L (n = 244)

CRP levels > 3.0 mg/L (n = 205)

Crude RR of CRP >3.0 mg/L (95% CI)

Adjusted RRaof CRP >3.0 mg/L (95% CI)

CRP levels <3.0 mg/L (n = 388)

CRP levels > 3.0 mg/L (n = 200)

Crude RR of CRP >3.0 mg/L (95% CI)

Adjusted RRaof CRP >3.0 mg/L (95% CI)

 

N (%)

N (%)

  

N%

N%

  

Age

        

Age < 40 years

8 (35)

15(65)

1.73 (1.23-2.43)

1.41 (0.97-2.04)

18 (59)

13 (41)

1.34 (0.89-2.17)

1.61 (1.03-2.52)

Age 40-59 years

84 (46)

98 (54)

1.43 (1.16-1.76)

1.35 (1.09-1.66)

145 (62)

90 (38)

1.26 (1.00-1.59)

1.30 (1.03-1.62)

Age 60+ years

152 (62)

92(38)

1

1

224 (70)

97 (30)

1

1

Charlson comorbidity index score

        

0

172 (55)

139 (45)

1

1

283 (70)

119 (30)

1

1

1-2

57 (52)

54 (48)

1.10 (0.86-1.37)

1.15 (0.91-1.44)

92 (59)

63 (41)

1.37 (1.0-1.75)

1.47 (1.15-1.89)

3+

15 (56)

12 (44)

0.99 (0.64-1.54)

1.03 (0.66-1.60)

13 (42)

18 (58)

1.96 (1.40-2.74)

2.01 (1.44-2.98)

Any previous cardiovascular disease

        

No

213 (54)

189 (46)

1

1

307 (69)

139 (31)

1

1

Yes

31 (51)

30 (49)

1.05 (0.79-1.38)

1.18 (0.90-1.56)

81 (57)

61 (43)

1.38 (1.09-1.74)

1.50 (1.17-1.91)

High alcohol intake b

        

No

235 (54)

196 (46)

1

1

347 (65)

183 (35)

1

1

Yes

9 (50)

9 (50)

1.10 (0.68-1.77)

1.20 (0.77-1.87)

41 (70)

17 (30)

0.85 (0.56-1.28)

0.88 (0.59-1.32)

Physical activity

        

Regular

118 (59)

84 (41)

1

1

146 (75)

48 (25)

1

1

None

126 (51)

121(49)

1.18 (0.96-1.45)

1.14 (0.93-1.40)

242 (61)

142 (39)

1.49 (1.13-1.97)

1.46 (1.11-1.91)

Central obesity c

        

No

22 (81)

5 (19)

1

1

40 (77)

12 (23)

1

1

Yes

222 (53)

200 (47)

2.55 (1.15-5.68)

2.27 (1.00-5.16)

347 (65)

188 (35)

1.52 (0.91-2.53)

1.42 (0.83-2.41)

Weight gain >30 kg since 20 years of age

        

No

164 (61)

103 (39)

1

1

256 (72)

100 (28)

1

1

Yes

80 (44)

102 (56)

1.45 (1.19-1.77)

1.36 (1.11-1.66)

132 (57)

100 (43)

1.54 (1.23-1.92)

1.42 (1.13-1.78)

Antihypertensive treatment

        

No

75 (67)

56 (43)

1

1

126 (70)

52 (30)

1

1

Yes

169 (21)

149(47)

1.10 (0.87-1.38)

1.23 (0.97-1.57)

162 (64)

148 (36)

1.63 (1.26-2.11)

1.24 (0.95-1.62)

Statin treatment

        

No

61 (43)

83 (57)

1

1

124 (64)

66 (35)

1

1

Yes

183 (60)

122 (40)

0.69 (0.57-0.84)

0.75 (0.61-0.91)

264 (66)

134 (34)

0.96 (0.76-1.23)

0.96 (0.41-1.89)

  1. aAdjusted for age, gender, central obesity, comorbidity, physical activity and alcohol consumption (except when stratified by given variable).
  2. bHigh alcohol intake defined as (≥14/21 alcoholic drinks/week for women/men).
  3. cCentral obesity defined as waist circumference ≥94 cm men/≥80 cm women.
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us